SPRC — SciSparc Ltd.

Nasdaq · Health Care · Pharmaceuticals · CIK 1611746 ·
Last close
$4.47
Market Cap
$2.57M
52W High
$9.03
52W Low
$2.98
ADV30
683,239
Next earnings
SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company sells hemp seed oil-based products and others. The company has an agreement with Procaps to develop and commercially manufacture SCI-110, palmitoylethanolamide oral tablets and CannAmide in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Dec 2025 7,622,000 4,591,000 2,475,000
Jun 2025 5,139,000 1,545,000 5,220,000
Dec 2024 10,347,000 1,540,000 1,408,000

Balance + Analyst (yfinance extras)

Retained Earnings
$-87,154,000
Inventory
$75,000
Receivables
$662,000
ST Investments
$0
EBIT TTM
Pretax Income TTM
Interest Exp TTM
Analysts

Yahoo Snapshot (yfinance, live)

Total Revenue
$856,000
EBITDA
$-5,794,000
Free Cash Flow
$1,602,500
Enterprise Value
$-1,766,554
Total Cash
$4,591,000
Total Debt
$356,000
Shares Out
573,243
Trailing EPS
$98.07
Book Value
$142.32
ROE
-178.4%
ROA
-41.9%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 856,000 -8,749,000 -12,179,000 7,622,000 2,475,000 -4,137,000
Dec 2024 1,306,000 -7,242,000 -6,284,000 10,347,000 1,408,000 -5,104,000
Dec 2023 2,879,000 -5,773,000 -5,122,000 11,182,000 1,595,000 -5,887,000
Dec 2022 1,347,000 -8,287,000 -2,592,000 10,605,000 4,156,000 -7,917,000

Peers — same industry

TickerNameMarket CapLastDaily %
PKTX ProtoKinetix, Inc. $2.60M $0.01
CPMD CANNAPHARMARX, INC. $2.51M $0.00
CMND Clearmind Medicine Inc. $2.64M $2.59
LIFD LFTD PARTNERS INC. $2.67M $0.18
OGEN ORAGENICS INC $2.67M $0.59

News headlines (Yahoo Finance, 1h cache)

SciSparc: NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy
2026-03-16 12:20 · Yahoo
NeuroThera Labs - Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy
2026-03-16 11:30 · Yahoo
Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy
2026-03-13 11:45 · Yahoo
SciSparc: NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease
2026-03-12 11:55 · Yahoo
NeuroThera Labs Announces Publication of International Patent in Collaboration With Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease
2026-03-11 11:30 · Yahoo
SciSparc: Subsidiary NeuroThera Labs (75%) Signs Definitive Agreement to Acquire Majority Stake in CliniQuantum, Innovator in Quantum-based Clinical trails
2026-03-10 13:28 · Yahoo
Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease
2026-03-10 12:59 · Yahoo
Neurothera Labs Inc. Announces Definitive Agreement to Acquire Majority Stake in Cliniquantum Ltd.
2026-03-10 11:30 · Yahoo
SciSparc announces 1-for-9 reverse share split
2026-03-03 13:23 · Yahoo
SciSparc: NeuroThera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSA
2026-02-02 13:24 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.